INNOVA CAPTAB LIMITED 1281/1, Hilltop Industrial Estate, Near EPIP, Phase-I, Jharmajri, Baddi, Dist.

Solan (H.P.)-173205 India. Phone: +91-1795-650820



November 06, 2024

To,

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 BSE Symbol: INNOVACAP

BSE Scrip Code: 544067

Dear Sir/Madam,

To,

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor Plot No. C/1, "G" Block Bandra-Kurla Complex Bandra (E), Mumbai – 400 051

NSE Symbol: INNOVACAP

<u>Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)</u> Regulations, 2015 - Grant of License

Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations"), we wish to inform you that our upcoming Jammu Facility received "Drug Manufacturing License" vide Letter No. CLJK202406146 dated November 06, 2024 from Government of Jammu and Kashmir, Department of Health and Medical Education, Drug Control Organisation, Jammu.

The required information in compliance with SEBI Circular ref. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, pertaining to the above license are provided in **Annexure A.**

The aforesaid information is also being placed on the website of the Company at www.innovacaptab.com

We request you to take the same on your record.

Thanking you,

Yours faithfully,

For Innova Captab Limited

Neeharika Shukla Company Secretary & Compliance Officer Membership No.: A42724

Encl: A/a

INNOVA CAPTAB LIMITED 1281/1, Hilltop Industrial Estate, Near EPIP, Phase-I, Jharmajri, Baddi, Dist.

Solan (H.P.)-173205 India. Phone: +91-1795-650820



Annexure-A

<u>Disclosure under Para B of Part A of Schedule III to the Regulation 30 of the SEBI Listing Regulations:</u>

No.	Items of Disclosure	Description
1.	Name of the Regulatory or Licensing	Government of Jammu & Kashmir,
	Authority	Department of Health and Medical Education,
		Drugs Control Organization,
		Jammu and Kashmir,India
2.	Brief details of the approval/license	License to Manufacture for Sale or for Distribution of
	obtained	Drugs.
3.	Impact/relevance of such	Grant of License to Manufacture Drugs
	approval/license	
4.	Period for which such	November 05, 2029
	approval/license is/was valid	